ERBB2 and inflammatory breast carcinoma: The combination of paclitaxel with anti-HER2 agents trastuzumab and pertuzumab is currently under investigation as neoadjuvant therapy for HER2-positive IBC (NCT01796197), though results have not yet been posted.